Literature DB >> 12169239

Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Gerald V Naccarelli1, John Hynes, Deborah L Wolbrette, Luna Bhatta, Mazhar Khan, Jerry Luck.   

Abstract

In managing atrial fibrillation, the main therapeutic strategies include rate control, termination of the arrhythmia, and pr vention of recurrences and thromboembolic events. Rate control with digoxin, b-blockers, verapamil, and diltiazem may be preferred in drug refractory and sedentary patients with markedly dilated left atrium and atrial fibrillation of long duration. Drugs useful in the maintenance of sinus rhythm include quinidine, procainamide, disopyramide, sotalol, amiodarone, dofetilide, flecainide, and propafenone. In patients with structural heart disease, the class III antiarrhythmics are the initial drugs of choice, given their neutral effects on survival in a post-myocardial infarction and congestive heart failure population. Due to high recurrence rates with pharmacologic therapy, nonpharmacologic options of therapy include atrioventricular junction ablation, atrial defibrillators, catheter ablation of pulmonary vein foci, and attempts to perform an atrial Maze procedure using catheters. Hybrid therapy using drugs in combination with nonpharmacologic approaches will be used more frequently in the future for refractory patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169239     DOI: 10.1007/s11886-002-0042-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  88 in total

Review 1.  Tachycardia-induced atrial myopathy: an important mechanism in the pathophysiology of atrial fibrillation?

Authors:  M M Gallagher; O A Obel; J A Camm
Journal:  J Cardiovasc Electrophysiol       Date:  1997-09

Review 2.  The atrial defibrillator: a stand-alone device or part of a combined dual-chamber system?

Authors:  A Heisel; J Jung
Journal:  Am J Cardiol       Date:  1999-03-11       Impact factor: 2.778

3.  Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.

Authors:  E L Pritchett; E A McCarthy; W E Wilkinson
Journal:  Ann Intern Med       Date:  1991-04-01       Impact factor: 25.391

4.  The azimilide post-infarct survival evaluation (ALIVE) trial.

Authors:  A J Camm; R Karam; C M Pratt
Journal:  Am J Cardiol       Date:  1998-03-19       Impact factor: 2.778

Review 5.  A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators.

Authors:  G V Naccarelli; D L Wolbrette; J T Dell'Orfano; H M Patel; J C Luck
Journal:  J Cardiovasc Electrophysiol       Date:  1998-08

6.  The natural history of lone atrial fibrillation. A population-based study over three decades.

Authors:  S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

7.  Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.

Authors:  E L Pritchett; W E Wilkinson
Journal:  Am J Cardiol       Date:  1991-05-01       Impact factor: 2.778

8.  Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone.

Authors:  D L Disch; M L Greenberg; P T Holzberger; D J Malenka; J D Birkmeyer
Journal:  Ann Intern Med       Date:  1994-03-15       Impact factor: 25.391

Review 9.  Atrial fibrillation: natural history, complications, and management.

Authors:  J S Alpert; P Petersen; J Godtfredsen
Journal:  Annu Rev Med       Date:  1988       Impact factor: 13.739

10.  Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent.

Authors:  D David; E D Segni; H O Klein; E Kaplinsky
Journal:  Am J Cardiol       Date:  1979-12       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.